医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsubishi Electric to Install Proton Beam Therapy System at Tsuyama Chuo Hospital in Okayama, Japan

2013年10月01日 AM11:40
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has signed an agreement to provide its proprietary proton beam therapy system for cancer treatment to Tsuyama Chuo Hospital, led by Yoshinori Ukita, president of Tsuyama Jifu Group, in Okayama. This will be the first particle therapy system in the Chugoku-Shikoku region, significantly expanding access to patients in southern Japan. The system will be part of a new treatment center expected to open in March 2016 that will be jointly operated with Okayama University.

Proton Beam Therapy System

The proton system features the new Universal Nozzle with high dose-rate capability. Testing is being performed using an in-house test proton beam facility at Mitsubishi Electric’s Kobe factory to obtain government approval in a timely manner. Mitsubishi Electric also provides staff training and commissioning support to facilitate the early start up of treatment.

New Treatment Center

Okayama University / Tsuyama Chuo Hospital Proton Beam Cancer Center, which is led by Shigeatsu Fujiki, president of Tsuyama Chuo Hospital, Kiyoshi Morita, president of Okayama University and Susumu Kanazawa, professor and chairman of Department of Radiology, Okayama University Medical School, will offer proton cancer treatment through research and education.

To date, Mitsubishi Electric has installed systems at eight of the 11 facilities in Japan, and more than 16,000 patients have been treated at these facilities. Tsuyama Chuo Hospital will be the ninth facility to carry Mitsubishi Electric therapy systems.

Mitsubishi Electric will continue to provide and develop advanced particle therapy systems for use worldwide, and is committed to providing superb operational and maintenance support.

 
Facility   Prefecture   Year   Ion Species
National Institute of Radiological Sciences

(Coordinating underwriter: Mitsubishi Electric)

Chiba 1994 carbon
Hyogo Ion Beam Medical Center Hyogo 2001 proton/carbon
Shizuoka Cancer Center Shizuoka 2003 proton
Southern TOHOKU Proton Therapy Center Fukushima 2008 proton
Gunma University Heavy Ion Medical Center Gunma 2010 carbon
Fukui Prefectural Hospital Proton Beam Cancer Treatment Center Fukui 2011 proton
Medipolis Medical Research Institute Kagoshima 2011 proton
SAGA Heavy Ion Medical Accelerator in Tosu Saga 2013 carbon
Okayama University / Tsuyama Chuo Hospital Proton Beam Cancer Center   Okayama   2016

(plan)

  proton
 

About Mitsubishi Electric

With over 90 years of experience in providing reliable, high-quality products, Mitsubishi Electric Corporation (TOKYO: 6503) is a recognized world leader in the manufacture, marketing and sales of electrical and electronic equipment used in information processing and communications, space development and satellite communications, consumer electronics, industrial technology, energy, transportation and building equipment. Embracing the spirit of its corporate statement, Changes for the Better, and its environmental statement, Eco Changes, Mitsubishi Electric endeavors to be a global, leading green company, enriching society with technology. The company recorded consolidated group sales of 3,567.1 billion yen (US$ 37.9 billion*) in the fiscal year ended March 31, 2013. For more information visit http://www.MitsubishiElectric.com

*At an exchange rate of 94 yen to the US dollar, the rate given by the Tokyo Foreign Exchange Market on March 31, 2013

CONTACT

Mitsubishi Electric Corporation
Customer Inquiries
Advanced
Magnetic and Medical Systems Marketing Department
pmd.pt@pz.MitsubishiElectric.co.jp
http://www.MitsubishiElectric.com/products/public/particle/index.html
or
Media
Inquiries

Katsunobu Muroi, +81-3-3218-2346
Public
Relations Division
prd.gnews@nk.MitsubishiElectric.co.jp
http://www.MitsubishiElectric.com/news/

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent